Zhejiang Xianju Pharmaceutical Co.,Ltd. (SHE:002332)
9.14
+0.04 (0.44%)
Feb 3, 2026, 3:04 PM CST
SHE:002332 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,568 | 3,980 | 4,079 | 4,358 | 4,335 | 4,002 |
Other Revenue | 21.17 | 21.17 | 43.96 | 21.52 | 22.46 | 16.91 |
| 3,589 | 4,001 | 4,123 | 4,380 | 4,357 | 4,019 | |
Revenue Growth (YoY) | -12.95% | -2.98% | -5.85% | 0.52% | 8.42% | 8.37% |
Cost of Revenue | 1,341 | 1,744 | 1,972 | 1,865 | 1,848 | 1,801 |
Gross Profit | 2,249 | 2,256 | 2,152 | 2,515 | 2,509 | 2,218 |
Selling, General & Admin | 1,487 | 1,344 | 1,271 | 1,532 | 1,560 | 1,344 |
Research & Development | 278.85 | 265.17 | 261 | 266.77 | 243.37 | 208.39 |
Other Operating Expenses | 25.86 | 19.26 | 22.04 | 32.92 | 32.73 | 34.43 |
Operating Expenses | 1,801 | 1,639 | 1,547 | 1,836 | 1,836 | 1,578 |
Operating Income | 447.51 | 617.42 | 604.79 | 678.81 | 672.92 | 640.05 |
Interest Expense | -4.97 | -3.13 | -3.37 | -6.29 | -23.1 | -49.23 |
Interest & Investment Income | 4.97 | 29.48 | 38.28 | 76.54 | 43.19 | 14.97 |
Currency Exchange Gain (Loss) | 10.57 | 10.57 | -9.32 | 11.8 | 17.44 | -25.01 |
Other Non Operating Income (Expenses) | -10.91 | -2.7 | -5.53 | -11.25 | -5.26 | -18.64 |
EBT Excluding Unusual Items | 447.17 | 651.63 | 624.85 | 749.6 | 705.19 | 562.13 |
Gain (Loss) on Sale of Investments | -20.39 | -8.14 | -8.97 | -0 | 0.64 | - |
Gain (Loss) on Sale of Assets | 47.28 | 0.28 | -1.48 | 91.62 | 14.51 | -0.74 |
Asset Writedown | -1.96 | -1.31 | -0.42 | -0.91 | -1.68 | -1.12 |
Other Unusual Items | -170.81 | -170.81 | 27.7 | 31.58 | 11.2 | 32.36 |
Pretax Income | 327.97 | 498.33 | 641.68 | 871.89 | 729.87 | 621.25 |
Income Tax Expense | 74.87 | 98.4 | 79.56 | 124.49 | 108.6 | 92.25 |
Earnings From Continuing Operations | 253.1 | 399.92 | 562.12 | 747.4 | 621.26 | 529 |
Minority Interest in Earnings | 20.59 | -2.74 | 0.97 | 2.01 | -1.94 | -24.49 |
Net Income | 273.68 | 397.18 | 563.08 | 749.41 | 619.33 | 504.51 |
Net Income to Common | 273.68 | 397.18 | 563.08 | 749.41 | 619.33 | 504.51 |
Net Income Growth | -55.98% | -29.46% | -24.86% | 21.00% | 22.76% | 22.94% |
Shares Outstanding (Basic) | 993 | 993 | 988 | 989 | 989 | 917 |
Shares Outstanding (Diluted) | 993 | 993 | 988 | 989 | 989 | 917 |
Shares Change (YoY) | 0.54% | 0.51% | -0.13% | 0.00% | 7.84% | 0.59% |
EPS (Basic) | 0.28 | 0.40 | 0.57 | 0.76 | 0.63 | 0.55 |
EPS (Diluted) | 0.28 | 0.40 | 0.57 | 0.76 | 0.63 | 0.55 |
EPS Growth | -56.21% | -29.83% | -24.76% | 21.00% | 13.84% | 22.22% |
Free Cash Flow | 104.27 | 191.07 | 360.85 | 326.74 | 409.31 | 671.06 |
Free Cash Flow Per Share | 0.10 | 0.19 | 0.36 | 0.33 | 0.41 | 0.73 |
Dividend Per Share | 0.400 | 0.300 | 0.300 | 0.300 | 0.150 | 0.150 |
Dividend Growth | 33.33% | - | - | 100.00% | - | 50.00% |
Gross Margin | 62.64% | 56.40% | 52.18% | 57.42% | 57.58% | 55.18% |
Operating Margin | 12.47% | 15.43% | 14.67% | 15.50% | 15.44% | 15.93% |
Profit Margin | 7.63% | 9.93% | 13.66% | 17.11% | 14.21% | 12.55% |
Free Cash Flow Margin | 2.90% | 4.78% | 8.75% | 7.46% | 9.39% | 16.70% |
EBITDA | 670.11 | 835.24 | 816.24 | 866.26 | 857.11 | 817.16 |
EBITDA Margin | 18.67% | 20.88% | 19.79% | 19.78% | 19.67% | 20.33% |
D&A For EBITDA | 222.6 | 217.82 | 211.45 | 187.46 | 184.19 | 177.11 |
EBIT | 447.51 | 617.42 | 604.79 | 678.81 | 672.92 | 640.05 |
EBIT Margin | 12.47% | 15.43% | 14.67% | 15.50% | 15.44% | 15.93% |
Effective Tax Rate | 22.83% | 19.75% | 12.40% | 14.28% | 14.88% | 14.85% |
Revenue as Reported | 3,589 | 4,001 | 4,123 | 4,380 | 4,357 | 4,019 |
Advertising Expenses | - | 712.54 | 685.06 | 991.03 | 1,035 | 864.56 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.